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ABSTRACT 
In order to probe structure-activity relationships of association with ferriprotoporphyrin IX 
(log K) and inhibition of -hematin formation, a series of 4-aminoquinolines with varying 
substituents at the 7-position (X) have been synthesized. These have been further elaborated 
by introduction of two different R groups on the 4-amino nitrogen atom in the form of methyl 
(R = Me) and ethylamine (R = EtNH2) side chains. Data for a previously investigated series 
containing an N,N-diethyl-ethylamine side chain were also compared with the findings of this 
study. Experimentally, log K values for the simple 4-aminoquinoline series (R = H) were 
found to correlate with the hydrophobicity constant () of the group X. The log K values for 
the series with R = Me and EtNH2 were found to correlate with those of the series with R = 
H. The log of the 50% -hematin inhibitory activity (log BHIA50) was found to correlate with 
log K and either meta (m) or para (p) Hammett constants for the series with R = Me and 
EtNH2, but not the simple series with R = H. To further improve predictability, correlations 
with ab initio electrostatic parameters, namely Mulliken and CHelpG charges were 
investigated. The best correlations were found with CHelpG charges which indicated that log 
K values can be predicted from the charges on atom H-8 and the group X in the quinolinium 
species computed in vacuum, while log BHIA50 values can be predicted from the CHelpG 
charges on C-7, C-8 and N-1 for the neutral species in vacuum. These correlations indicate 
that association and inhibition of -hematin formation are separately determined. They also 
suggest that electron withdrawing groups at the 7-position, but not necessarily hydrophobic 
groups are required for hemozoin inhibition. The upshot is that the correlations imply that 
considerably more hydrophilic hemozoin inhibitors are feasible. 
Keywords: hemozoin; DFT; antimalarials; quinolines; structure-activity relationships; 
ferriprotoporphyrin IX  
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1. Introduction 
 Quinoline antimalarials such as quinine and chloroquine have had a long and 
successful history.
1
 Subsequent emergence of chloroquine resistance has led to the use of 
other quinoline derivative antimalarials such as mefloquine and amodiaquine. Indeed, the 
development and clinical deployment of new quinoline antimalarials continues to this day. 
For example, piperaquine, a bis-4-aminoquinoline effective against chloroquine-resistant 
strains that consists of two 4-aminoquinoline moieties attached by a linker has only recently 
been introduced into clinical use.
2
 Ferroquine, a 4-amino-7-chloroquinoline with a ferrocenyl 
side-chain is currently in phase IIB clinical trials.
3
 In addition, research on new quinoline 
antimalarials retains considerable interest, such as that on so-called “reversed chloroquines” 
and related compounds that are both antimalarially active and inhibit the chloroquine 
resistance mechanism of the parasite.
4-10
 
 The class of 4-aminoquinoline antimalarials are believed to act by inhibiting the 
incorporation of ferriheme (Fe(III)PPIX), a toxic by-product of hemoglobin digestion, into 
hemozoin. This is a less toxic insoluble microcrystalline form of Fe(III)PPIX which is 
produced in the acidic digestive vacuole of the malaria parasite. Indeed, recently chloroquine 
has been shown to increase free Fe(III)PPIX and decrease hemozoin in the P. falciparum cell 
in a dose-dependent manner.
11
 The detailed mechanism of inhibition has been a matter of 
debate, with one school of thought proposing that it involves complex formation in 
solution,
12-14
 while another postulates inhibition of crystal growth via interaction with the 
crystal surface.
15
 It is known that quinolines form complexes with Fe(III)PPIX in 
solution,
12,16
 while it is also the case that the inhibitory effects of these compounds can be 
described by a surface interaction model.
15,17,18
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  Despite the good efficacy of 4-aminoquinolines in treating malaria, a number of 
adverse drug effects are known for this class of compound. One of the most important drug 
liabilities is cardiotoxicity.
19
 The human ether-a-go-go related gene (hERG) encodes a K
+
 
channel that plays a key role in regulating cardiac action potential.
20
 Inhibition of this channel 
can lead to arrhythmias and in extreme cases heart failure. Cytochrome P450 enzymes 
(CYPs) are known to be inhibited by many drug candidates and also represent a potential 
liability for 4-aminoquinolines.
21
 Indeed, Gleeson has shown that weak base compounds, of 
which the 4-aminoquinolines are an example, commonly exhibit adverse properties with 
respect to hERG toxicity and CYP inhibition. However, the likelihood of such liabilities is 
reduced in compounds that have decreased lipophilicity (clog P < 4) and relatively low 
molecular weight (< 400).
22
 Thus, suitably modified quinolines may exhibit improved drug 
toxicity profiles. 
   In order to design 4-aminoquinolines with improved toxicity profiles, it is a 
prerequisite to have an understanding of structure-activity relationships at the target level. A 
large number of 4-aminoquinolines with activity against the parasite are known, but these 
data are often difficult to interpret because of the complexity of the biological system, which 
includes factors such as accumulation in the digestive vacuole, access to the parasite and 
lipophilicity. A number of studies have been undertaken investigating effects of quinoline 
structure on Fe(III)PPIX association and inhibition of synthetic hemozoin (-hematin) 
formation.
23-29
 Some of these have been qualitative, while others have provided some 
quantitative information. In some cases however, it has been difficult to account for the 
strong activity of 4-amino-7-chloroquinolines relative to other 4-aminoquinolines.
24,28
 
 Here we have conducted a structure-activity relationship study to establish the 
minimum structural criteria for Fe(III)PPIX association and -hematin inhibition in this class 
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of compound. In this endeavor we have started with a series of simple 4-aminoquinolines and 
built up the lateral side chain to determine the effects on both association constant with 
Fe(III)PPIX (log K) and 50% -hematin inhibitory activity (BHIA50). This involved 
preparation of a series of 4-aminoquinolines in which the group at position 7 of the quinoline 
ring (X) and the lateral side-chain on the 4-amino group (R) were varied (Scheme 1), as well 
as comparisons with a previous series (R = EtN(Et)2 in Scheme 1) prepared in our 
laboratory.
24
 The values of log K and log BHIA50 were then correlated with empirical 
properties, namely hydrophobicity and Hammett constants and correlations between log 
BHIA50 and measured log K values were also explored. Furthermore, correlations with 
atomic charges, computed using density functional theory (DFT), were also investigated. 
 
 
 
 
Scheme 1 
2. Results 
Previous studies on 4-aminoquinolines have shown that association constants with 
Fe(III)PPIX and ability to inhibit -hematin formation depend on both lipophilic and 
electronic properties of the group at position 7.
23-25
 For this reason, a series of 4-
aminoquinolines with various substituents at position 7 (X) were chosen (Scheme 1). This 
was done with the aid of a Craig plot of Hammett constant (p) versus lipophilicity constant 
() so as to minimize correlation between these two properties.30 They were prepared 
according to well established procedures. Briefly, five 4-chloro-7-X-quinolines were 
5
8
6
7
4 3
N
1
2
NH
R
X
R = H (9) and X = Me (a), CF
3
 (b), Cl (c), CONH
2
 (d), CN (e), H (f), NH
2
 (g), NO
2
 (h), OMe (i)
R = Me (10) and X = Me (a), CF
3
 (b), Cl (c), CONH
2
 (d), CN (e), H (f), NH
2
 (g), NO
2
 (h), OMe (i)
R = EtNH
2
 (11) and X = Me (a), CF
3
 (b), Cl (c), CN (e), H (f), NO
2
 (h), OMe (i) 
R = EtN(Et)
2
 (13) and X = Me (a), CF
3
 (b), Cl (c), H (f), NH
2
 (g), NO
2
 (h), OMe (i), F (j), Br (k), I (l)
6 
 
synthesized either by reaction of meta-substituted anilines with diethyl 
ethoxymethylenemalonate in a five step process with moderate yields or by reaction of the 
aniline with Meldrum’s acid (2,2-dimethyl-1,3-dioxane-4,6-dione) and triethyl orthoformate 
in a two-step process. Three additional 4-chloro-7-X-quinolines were commercially available 
(X = Cl, H and CF3). Further modifications to these 7-substituted quinolines were made by 
varying the lateral side chain at position 4 (Scheme 1). This was accomplished by 
displacement of the 4-chloro group in an aromatic substitution reaction with either ammonia 
or two primary amines, namely methylamine or ethanediamine. Finally, compounds with X = 
NH2 were prepared from the corresponding 7-nitroquinoline by reduction with SnCl2. Full 
synthetic details for all of the above reactions are supplied as supplementary content. 
For each of the compounds synthesized, the log K with Fe(III)PPIX was measured in 
40% (v/v) aqueous DMSO. Uv-visible spectroscopic changes were consistent with those 
reported for compounds which -stack in solution.31 In addition, all compounds were tested 
for inhibition of -formation mediated by acetate. The conditions used for measurement of 
these quantities were chosen to facilitate comparison with previously collected data for a 
related series of compounds with a N,N-diethylaminoethyl side chain (R = EtN(Et)2 in 
Scheme 1).
24
 Values of log K and the 50% -hematin inhibitory activity (BHIA50) are 
presented in Table 1. 
In a previous study of 4-aminoquinolines with R = EtN(Et)2, it was found that log K is 
correlated with the substituent hydrophobicity constant () of the X substituent.24 A similar 
correlation is observed for the series prepared here with R = H (Figure 1a). The same trend is 
also seen with clog P (not shown). These correlations suggest that the association of the 4-
aminoquinoline with Fe(III)PPIX becomes stronger as the substituent X becomes more 
lipophilic. No correlation between log K and substituent constants was found for the series 
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with R = Me or EtNH2. However, a statistically significant correlation (P < 0.05) was found 
between the log K values for these two series and those for the series with R = H (Figure 1b 
and c). On the other hand, no correlation of log K for the series with R = EtN(Et)2 with log K 
for the series with R = H was found. 
 
Table 1 Log K with Fe(III)PPIX and (BHIA50) for 4-aminoquinolines. 
R X Compound log K BHIA50
a 
H CH3 9a 4.17  0.03 
b 
10.8  0.6 b 
H CF3 9b 4.41  0.01 
b
 5.6  0.7 b 
H Cl 9c 5.01  0.06 b 5.8  0.9 b 
H CONH2 9d 3.76  0.12
 b
 10.3  0.4 b 
H CN 9e 4.32  0.28 b 6.1  0.9 b 
H H 9f 3.83  0.02 b 10.0  0.3 b 
H NH2 9g 3.44  0.20
 b
 > 20
 b
 
H NO2 9h 4.57  0.11
 b
 5.7  0.6 b 
H OCH3 9i 4.24  0.02
 b
 15.6  0.5 b 
CH3 CH3 10a 4.01  0.01
 b
 11.1  0.9 b 
CH3 CF3 10b 4.18  0.02
 b
 5.0  0.4 b 
CH3 Cl 10c 4.62  0.03
 b
 5.7  0.5 b 
CH3 CONH2 10d 3.43  0.07
 b
 10.1  0.5 b 
CH3 CN 10e 4.42  0.03
 b
 4.5  0.3 b 
CH3 H 10f 3.92  0.01
 b
 14.9  0.3 b 
CH3 NH2 10g 4.04  0.01
 b
 >20
 b
 
CH3 NO2 10h 4.32  0.08
 b
 5.5  0.3 b 
CH3 OCH3 10i 3.71  0.03
 b
 10.4  0.3 b 
CH2CH2NH2 CH3 11a 4.35  0.01
 b
 10.3  0.3 b 
CH2CH2NH2 CF3 11b 4.70  0.01
 b
 5.4  0.2 b 
CH2CH2NH2 Cl 11c 5.10  0.01
 b
 5.4  0.5 b 
CH2CH2NH2 CN 11e 4.47  0.03
 b
 6.3  0.8 b 
CH2CH2NH2 H 11f 4.38  0.03
 b
 10.6  0.4 b 
CH2CH2NH2 NO2 11h 4.48  0.07
 b
 5.3  0.4 b 
CH2CH2NH2 OCH3 11i 4.47  0.01
 b
 10.6  0.3 b 
CH2CH2N(CH2CH3)2 CH3 13a 4.86  0.01 
c 
 17  4 c 
CH2CH2N(CH2CH3)2 CF3 13b 4.67  0.02
 c
 8  2 c 
CH2CH2N(CH2CH3)2 Cl 13c 5.81  0.01
 c
 2.2  0.2 c 
CH2CH2N(CH2CH3)2 F 13j 4.60  0.02
 c
 9.7  0.8 c 
CH2CH2N(CH2CH3)2 Br 13k 4.99  0.01
 c
 4.4  0.7 c 
CH2CH2N(CH2CH3)2 I 13l 5.02  0.02
 c
 2.8  0.2 c 
CH2CH2N(CH2CH3)2 H 13f 4.75  0.03
 c
 >20
 c
 
CH2CH2N(CH2CH3)2 NH2 13g 4.35  0.02
 c
 >20
 c
 
CH2CH2N(CH2CH3)2 NO2 13h 4.65  0.02
 c
 3.1  0.6 c 
CH2CH2N(CH2CH3)2 OCH3 13i 4.83  0.01
 c
 >20
 c
 
a 
Equivalents relative to Fe(III)PPIX; 
b
 this study; 
c
 from Kaschula et al.
24
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Figure 1. Experimentally observed correlations of log K and log BHIA50. (a) Single linear correlation of log K 
versus  for the series where R = H. Values of  were obtained from Hansch and Leo.32 Log K = 0.4(2) + 
4.3(1), r
2
 = 0.48, P = 0.039. (b) Single linear correlation of log K of the series where R = Me versus log K of the 
series where R = H. Log K (R = Me) = 0.5(2)log K (R = H) + 1.8(9), r
2
 = 0.48, P = 0.038. (c) Single linear 
correlation of log K of the series where R = EtNH2 versus log K of the series where R = H. Log K (R = EtNH2) 
= 0.6 (2)log K (R = H) + 1.9(7), r
2
 = 0.73, P = 0.014. (d) Multiple linear correlation of log BHIA50 with log K 
and m for the series R = Me showing the calculated versus observed log BHIA50 values. Calculated values 
given by log BHIA50 = 0.2(1)log K  0.5(1)m + 1.8(4), r
2
 = 0.86, F = 15.5 (> F
0.99
 = 13.27). (e) Multiple linear 
correlation of log BHIA50 with log K and p for the series R = Me showing the calculated versus observed log 
BHIA50 values. Calculated values given by log BHIA50 = 0.2(1)log K  0.3(1)p + 1.9(5), r
2
 = 0.79, F = 9.66 (> 
F
0.95
 = 5.79). (f) Multiple linear correlation of log BHIA50 with log K and p for the series R = EtNH2 showing 
the calculated versus observed log BHIA50 values. Calculated values given by log BHIA50 = 0.37(5)log K  
0.28(3)p + 2.1(2), r
2
 = 0.97, F = 69.19 (> F
0.99
 = 13.27). (g) Single linear correlation of log K for the series R = 
H with log BHIA50 of the series R = EtNH2. Log K = 1.9(7)log BHIA50 + 6.0(6), r
2
 = 0.58, P = 0.045. 
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In the earlier study, using multiple linear correlation analysis (MLCA), a correlation 
was also found between log BHIA50 and both log K & m.
24
 In the present work, a similar 
correlation was found in the series with R = Me (Figure 1d). In addition, log BHIA50 also 
correlated with both log K & p for both the series with R = Me and EtNH2 (Figure 1e and f). 
A further interesting observation was that there is a simple linear correlation between log 
BHIA50 for the series with R = EtNH2 and the log K values for the corresponding compounds 
in the R = H series (Figure 1g). A similar relationship was found between the R = Me and R 
= H series, but in this case the correlation between log BHIA50 and log K falls just short of 
statistical significance at the 95% confidence level. Thus, inhibition of -hematin formation 
appears to be favored by stronger association with Fe(III)PPIX and by more electron 
withdrawing X substituents. Somewhat surprisingly, no such correlation between log BHIA50 
and log K was found for the series with R = H itself. However, correlations were found 
between log BHIA50 for the series with R = H and those with R = Me and EtNH2. As in the 
case of log K, no such correlation was found for the series with R = EtN(Et)2. 
Given the role found for electronic properties (Hammett constants) in the inhibition of 
-hematin formation described above, it was decided to investigate whether there were any 
correlations between atomic charges on the quinoline moiety calculated using quantum 
mechanical methods and log K, log BHIA50, or both. For this purpose, Mulliken charges were 
calculated for all atoms in the entire series with R = H as well as three compounds not 
prepared in this study with R = H and X = F, Br and I. These were calculated for both the 
neutral and protonated positively charged (quinolinium) forms in both vacuum and aqueous 
medium using an implicit water model (SMD).
33
 In the case of log K, eight statistically 
significant (P < 0.05) correlations with single atomic charges were found. Using MLCA, two 
additional correlations were obtained. The best correlation was between log K and the 
charges on C-6 & C-8a calculated for the neutral form in water (see supplementary content 
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Figure S1). Association is predicted to be favored by greater negative charge on C-8a and 
reduced negative charge on C-6. However, values of log K predicted in this way do not 
correlate with experimental values for any of the other series. 
In the case of log BHIA50 many correlations with Mulliken atomic charges were 
found. However, an additional criterion could be used in the selection of more reliable 
predictors, namely the predicted activity of the compound with X = NH2.  Although no 
experimental values could be obtained for derivatives with X = NH2 because their -hematin 
inhibitory activities were found to be too weak to measure using the assay, these compounds 
could be used as test molecules. Only correlations which predicted the corresponding X = 
NH2 compound in the series to have a log BHIA50 higher than the maximum value tested (> 
1.3) were considered to be realistic. This additional constraint reduced the many correlations 
found by MLCA to just three. These correlations were found for the quinolinium species in 
both vacuum and water and involved atomic charges N-1 & H-8, N-1 & H-6 and N1 & H-1 
(see supplementary content Figure S2). The strongest correlation was between log BHIA50 
and N-1 & H-8, with increased activity favored by a less negative charge on N-1 and a more 
positive charge on H-8. The predicted log BHIA50 for this series were also then found to 
correlate significantly (P < 0.05) with the experimental log BHIA50 values for the series with 
R = Me, EtNH2 and EtN(Et)2. 
The electrostatic surface potential of a molecule is likely to be a major determinant of 
non-covalent interactions with other molecules given the prominent role of electrostatic 
forces in such interactions. The CHelpG charge scheme provides a model of electrostatic 
surface potential using localized atomic point charges. The possibility was therefore 
considered that these might provide better correlations than the Mulliken charges. CHelpG 
charges were therefore calculated for the same molecules as the Mulliken charges. Once 
11 
 
again, these were calculated for both the neutral and quinolinium forms in both vacuum and 
water. In the case of the series with R = H, there were three significant linear correlations 
with log K involving single atomic charges. Using MLCA with pairs of atomic charges eight 
further correlations of log K were found at or above the 95% confidence level. The strongest 
correlation was found using the MLCA approach and exhibited considerably greater 
statistical significance than the best correlation obtained with Mulliken charges (F = 26.0 
versus 6.3). This was for the quinolinium species in vacuum and involved atoms X & H-8 
(Figure 2a). The association with Fe(III)PPIX is favored by a more negative potential on X 
and a less positive potential on H-8, with the latter having a greater influence. By contrast to 
the results obtained using Mulliken charges, the log K values calculated from the relationship 
above using CHelpG charges produced a statistically significant linear correlation with the 
experimental log K values for the series with R = Me and EtNH2 (P < 0.05). In the case of the 
series with R = EtN(Et)2, the correlation is not statistically significant, albeit only by a small 
margin (Figure 2b – d). 
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Figure 2. Correlation of observed log K values with calculated log K values obtained for the quinolinium 
species with R = H using CHelpG charges on atom/group X and atom H-8, calculated in vacuum. (a) log K 
(obs.) for the series where R = H versus log K (calc.) for the same series obtained by multiple linear correlation. 
Calculated values given by log K = 3.6(8) X  21(3) H-8 + 7.6(5), r2 = 0.90, F = 25.95 (> F0.99 = 10.93). (b) 
Single linear correlation of log K (obs.) for the series where R = Me versus calculated log K values for the series 
where R = H as determined in (a), with r
2
 = 0.52 and P = 0.029. (c) Single linear correlation of log K (obs.) for 
the series where R = EtNH2 versus calculated log K values for the series where R = H as determined in (a), with 
r
2
 = 0.61 and P = 0.039. (d) Single linear correlation of log K (obs.) for the series where R = EtN(Et)2 versus 
calculated log K values for the series where R = H as determined in (a), with r
2
 = 0.37 and P = 0.061. 
 
As with the Mulliken charges, in the case of log BHIA50 only those correlations that 
successfully predicted the inactivity of compounds with X = NH2 were deemed worthy of 
consideration. For the series with R = H, nine correlations, four simple linear correlations and 
five multiple linear correlations involving pairs of charges were found. As observed in the 
case of log K, the strongest correlations obtained with CHelpG charges had considerably 
greater statistical significance than those obtained using Mulliken charges. In particular, two 
correlations found by MLCA were significant at better than the 99% confidence level in one 
case and 99.9% in the other. These involved charges calculated for the neutral species in 
vacuum on atoms N-1 & C-8 and N-1 & C-7 respectively (Figure 3a and b). As seen with the 
log K values, the predicted log BHIA50 values for this series were also then found to correlate 
significantly (P < 0.05) with the experimental log BHIA50 values for the series with R = Me 
and EtNH2. In addition, because CHelpG charges could be computed for further compounds 
not synthesized, a similar correlation was now uncovered with series with R = EtN(Et)2 
(Figure 3c – h). Thus, -hematin inhibitory activity was found to improve with decreasing 
negative potential on N-1, decreasing negative potential on C-8 and decreasing positive 
potential on C-7. 
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A notable observation is that as the lateral side chain becomes more lipophilic, the 
sensitivity of log BHIA50 to the identity of the X substituent decreases. This is observed as a 
decrease in slope in figures 3a – h as log P increases (see supplementary content Figure S3). 
 
Figure 3. Correlation of observed log BHIA50 values versus calculated log BHIA50 values obtained for the 
neutral species with R = H using CHelpG charges on atoms N-1 and C-8 (left panels) and atoms N-1 and C-7 
(right panels), calculated in vacuum. (a) Log BHIA50 (obs.) for the series where R = H versus log BHIA50 (calc.) 
for the same series obtained by multiple linear correlation. Calculated values given by log BHIA50 = 12(2) N-1 
 0.6(2) C-8  7(1), r2 = 0.96, F = 56.98 (> F0.99 = 13.27). (b) Log BHIA50 (obs.) for the series where R = H 
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versus log BHIA50 (calc.) for the same series obtained by multiple linear correlation. Calculated values given by 
log BHIA50 = 13(1) N-1 + 0.26(8) C-7  8(1), r
2
 = 0.97, F = 71.35 (> F
0.99
 = 13.27). (c) Single linear 
correlation of log BHIA50 (obs.) for the series where R = Me versus values of log BHIA50 calculated for the 
series where R = H as described in (a), with r
2
 = 0.60 and P = 0.024. (d) Single linear correlation of log BHIA50 
(obs.) for the series where R = Me versus values of log BHIA50 calculated for the series where R = H as 
described in (b), with r
2
 = 0.60 and P = 0.025. (e) Single linear correlation of log BHIA50 (obs.) for the series 
where R = EtNH2 versus values of log BHIA50 calculated for the series where R = H as described in (a), with r
2
 
= 0.80 and P = 0.007. (f) Single linear correlation of log BHIA50 (obs.) for the series where R = EtNH2 versus 
values of log BHIA50 calculated for the series where R = H as described in (b), with r
2
 = 0.79 and P = 0.008. (g) 
Single linear correlation of log BHIA50 (obs.) for the series where R = EtN(Et)2 versus values of log BHIA50 
calculated for the series where R = H as described in (a), with r
2
 = 0.73 and P = 0.015. (h) Single linear 
correlation of log BHIA50 (obs.) for the series where R = EtN(Et)2 versus values of log BHIA50 calculated for 
the series where R = H as described in (b), with r
2
 = 0.58 and P = 0.046. 
 In order to determine whether these observations are likely to be useful in designing 
new antimalarials, some of the compounds were tested for in vitro antimalarial activity 
against a chloroquine-sensitive strain of Plasmodium falciparum, NF54. Previous studies on 
closely related compounds have shown that a weak base N atom is required in the side chain 
for strong biological activity.
24
 This group causes the compound to pH trap in the acidic 
environment of the digestive vacuole of the parasite. For this reason, only the series with R = 
EtNH2 was investigated. The pKa values of the protonated terminal amino group and 
quinolinium N atom were estimated using the program MarvinSketch.
34
 These values, 
together with calculated log P values are reported in Table 2. Of particular note is the 7-CN 
compound. While it was not as active as the 7-Cl and 7-CF3 compounds, it nonetheless had a 
low IC50 of 20 nM. In keeping with previous studies,
8,24
 these compounds showed no direct 
correlation between IC50 for inhibition of parasite growth and BHIA50 (Figure 4a). However, 
when the vacuolar accumulation ratio was taken into account, a strong linear correlation was 
observed (Figure 4b). Comparison of lipophilicity and biological activity among this entire 
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series of compounds shows that the 7-CN group provides the best combination of strong 
activity and low lipophilicity (Figure 4c). 
Table 2 In vitro activity against the NF54 strain of P. falciparum, predicted vacuolar accumulation ratio (VAR) 
and calculated log P values for the compound series with R = EtNH2. 
X Compound pKa1
a 
pKa2
a
 VAR
b 
log P
c 
IC50 (nM) 
CH3 11a 8.51 9.65 58545 1.39 37 
CF3 11b 7.52 9.62 35894 1.80 8.6 
Cl 11c 7.30 9.62 27978 1.44 4.6 
CN 11e 5.85 9.62 1962 0.73 20 
H 11f 8.13 9.63 53181 0.92 66 
NO2 11h 5.31 9.62 753 0.87 747 
a
 calculated using MarvinSketch;
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b
 𝑉𝐴𝑅 =
1+10𝑝𝐾𝑎2−𝑝𝐻𝑣+10𝑝𝐾𝑎1+𝑝𝐾𝑎2−𝑝𝐻𝑣
1+10𝑝𝐾𝑎2−𝑝𝐻𝑒+10𝑝𝐾𝑎1+𝑝𝐾𝑎2−𝑝𝐻𝑒
,
24
 where pHv is the vacuolar pH 
taken as 5 and pHe is the external pH taken as 7.4; 
c
 calculated using MarvinSketch with the VG method. 
 
Figure 4. In vitro antimalarial activity of compounds 11a   h compared to -hematin inhibitory activity and log 
P. (a) No correlation was observed between BHIA50 and IC50 in the chloroquine-sensitive NF54 strain. (b) When 
the IC50 was corrected for predicted vacuolar accumulation through pH trapping there was a strong correlation 
with BHIA50. BHIA50 = 1.7(3) IC50VAR (mM) + 5.3(5), r
2
 = 0.87, P = 0.0064. (c) A plot of log P versus log 
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IC50 shows that this series of compounds fall into three categories. The 7-Cl, -CF3 and -CH3 derivatives 
displayed good activity (low log IC50), but high lipophilicity (top left quadrant), while the 7-H and 7-NO2 
derivatives showed weak activity, but low lipophilicity (bottom right quadrant). Only the 7-CN derivative 
displayed both strong activity and low lipophilicity (bottom left quadrant). 
 
3. Discussion  
 This study was designed to probe relationships between the structures of the simplest 
Fe(III)PPIX-associating and -hematin-inhibiting 4-aminoquinolines and their derivatives 
with the aim of determining the roles of the group at the 7-position and the lateral side chain 
in these interactions. This investigation also clarified, where possible, the relationship 
between Fe(III)PPIX binding and inhibition of β-hematin formation. To these ends, the 
simple undecorated 4-aminoquinoline derivatives (R = H), were used as the starting point. 
The side chain on the 4-amino group was then gradually built up to observe its effect, starting 
with a -CH3 group and then proceeding to an EtNH2 group. The association constants with 
Fe(III)PPIX and the inhibition of β-hematin formation values were found to be correlated, 
except in the series with R = H. The parameter π was found to correlate with log K in the case 
of the series with R = H, similar to that found previously by Kaschula et al. for the series with 
R = EtN(Et)2.
24
 The parameter p in combination with log K correlated with log BHIA50 of 
the series with R = Me and EtNH2, while m and log K correlated in the case where R = Me, 
similar to that found by Kaschula et al. in the case of the series with R = EtN(Et)2. The R = H 
series was also used to confirm that the quinoline ring is the primary component for the 
inhibition of β-hematin formation as previously suggested.23 These relationships all suggest 
that both an increase in association constant and the presence of an electron withdrawing 
group at the 7-position enhances inhibition of -hematin formation in this class of molecule. 
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 Calculated atomic charges, whether Mulliken or CHelpG charges obtained from 
quantum mechanical calculations were better predictors of log K than tabulated substituent 
constants. Specifically, the CHelpG charges were found to be the more predictive of the two 
and further discussion is limited to these. Charges on atom (or group) X together with H-8 for 
the quinolinium species in vacuum were found to be the major predictors of log K. Not only 
did they correlate strongly with log K for the series with R = H, but the predicted values for 
this series also cross-correlated with the experimental log K values for the series with R = Me 
and EtNH2. More specifically, increased negative potential on X and decreased positive 
potential on H-8 apparently favors association with Fe(III)PPIX. This is graphically 
illustrated by the electrostatic surface potential (ESP) shown in Figure 5a. 
 
Figure 5. Electrostatic surface potentials of species with R = H and X = NH2 (left panel) and Cl (right panel). 
Negative and positive potentials represented by red and blue shading respectively (a) Quinolinium species 
calculated in vacuum illustrating atoms/groups that predict association constants with Fe(III)PPIX. Association 
was found to be favored by increased negative potential at X (i) and decreased positive potential at H-8 (ii). (b) 
Neutral species calculated in vacuum illustrating atoms predictive of -hematin inhibition. Inhibition was found 
to be favored by decreased positive potential on C-7 (i) and decreased negative potential on both C-8 (ii) and N-
1 (iii). 
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Similarly atomic charges, particularly CHelpG charges, were good predictors of the 
trend in log BHIA50. Here, the best predictors were the CHelpG charges on N-1 and C-7, with 
N-1 and C-8 being almost as good. In contrast to the log K prediction, the neutral form (also 
in vacuum) was found to produce the strongest correlation. Decreased negative potential on 
N-1 in combination with either a less negative potential on C-8 or a less positive potential on 
C-7 was found to favor -hematin inhibition (Figure 5b). The predicted activities for the 
series with R = H again cross-correlated with the experimental values for the series with R = 
Me and EtNH2 and was even found to predict activities in the series reported by Kaschula et 
al. with R = EtN(Et)2.
24
 An interesting observation is that the sensitivity of log BHIA50 to the 
changes in ESP brought about by altering the X-substituent decreases as the lateral side chain 
becomes more lipophilic. 
 Several notable features emerge from this investigation. Atomic charges that predict 
log K are for the most part not the same as those that predict log BHIA50 and furthermore the 
correlations involve different species, namely quinolinium and neutral respectively. Indeed, 
in the case of the series with R = H there is no experimental correlation between log K and 
log BHIA50, suggesting that inhibition of -hematin formation is not directly related to 
association between Fe(III)PPIX and the 4-aminoquinoline compound in solution. This 
appears to support the hypothesis that inhibition of -hematin formation primarily occurs via 
interaction of the inhibitor with the growing crystal surface, rather than via complex 
formation in solution. It must be noted however, that there is some correlation between log K 
and log BHIA50 as the lateral side chain is lengthened. Thus, a role for solution association 
cannot necessarily be ruled out for all series of 4-aminoquinoline compounds. Finally, the 
correlation equations permit the prediction of both log K and log BHIA50 for these series of 4-
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aminoquinolines. Interestingly, they do not suggest that the lipophilicity of the group X plays 
a major role in -hematin inhibition. This is an important finding, since as noted in the 
introduction there is evidence that less lipophilic and lower molecular weight weak base 
compounds possess fewer undesirable drug liabilities, such as hERG toxicity. In this regard, 
it is worth remarking on the observed activity of the analogs with X = CN, which are 
relatively hydrophilic compared to those with X = Cl, but retain rather strong -hematin 
inhibitory activity. This indicates that 4-aminoquinolines with improved toxicity properties, 
but which maintain strong hemozoin-inhibiting characteristics are feasible. 
Preliminary investigation of biological activities of compounds in the series with R = 
EtNH2 indicate that these findings are indeed likely to be pertinent to the design of new 4-
aminoquinoline antimalarials. While there was no direct correlation between activity and 
strength of inhibition of -hematin formation, the correlation was strong if vacuolar 
accumulation through pH trapping was taken into account. This is consistent with previous 
studies on similar families of compounds.
8,24
 However, the strong activity of the 7-CN 
derivative, a compound with a particularly low lipophilicity is noteworthy. This contrasts 
with the 7-NO2 derivative which exhibited poor activity despite being a strong -hematin 
inhibitor. The weak activity of the latter compound can be ascribed to its particularly strong 
electron withdrawing effect. This lowers the pKa of the quinolinium NH
+
 group to such an 
extent that accumulation in the parasite digestive vacuole is too low for it to exert strong 
biological activity. On the other hand, the 7-CH3 and –H derivatives appear anomalously 
active given their weak inhibition of -hematin formation. In this case, the electron releasing 
characteristics of these groups ensure higher pKa values and hence greater vacuolar 
accumulation that compensates for weak -hematin inhibition. The 7-CN derivative presents 
the best compromise of properties if low lipophilicity is desired and is worth pursuing further. 
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4. Conclusion  
Compounds with electron withdrawing substituents, namely NO2, CN, Cl and CF3, 
were found to be strong inhibitors of β-haematin formation. Additionally, all of the 
hydrophilic and electron withdrawing compounds with X = CN were found to show strong 
inhibition of β-haematin formation. Analogs with electron releasing groups at the 7-position 
were found to be poor inhibitors or non-inhibitors of β-haematin formation. 
 Derivatives containing electron withdrawing groups at the 7-position were also found 
to bind strongly to Fe(III)PPIX, while those with electron releasing groups were weaker 
binders. Lipophilicity was found to be an important factor in Fe(III)PPIX binding. 
 The lateral side chain was found to play a positive role in Fe(III)PPIX binding. An 
increase in the length of the chain resulted in an increase in log K. The extension of the lateral 
side-chain was not found to have a significant impact on β-haematin inhibition, but was 
found to modulate the influence of the substituent at the 7-position. These findings could 
prove useful in the design of new 4-aminoquinoline -hematin inhibitors with potential 
antimalarial activity, especially in view of the observed good activity of the 7-CN derivative 
of the series with R = EtNH2. 
 
5. Experimental 
5.1 Synthesis 
Chemicals and solvents were purchased from Sigma-Aldrich Chemical Company or 
Fluka. Column chromatography was carried out using Silica gel 60 from Sigma-Aldrich. All 
products were characterized by 
1
H and 
13
C NMR and were recorded on a Bruker Avance (400 
MHz) or Varian EM (300 MHz) spectrometer. Compound identities were further confirmed 
by high resolution electrospray measurements performed on a Bruker Daltonis MicroOTOF 
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mass spectrometer. The purity of final compounds was confirmed by high performance liquid 
chromatography (HPLC). This was performed on a Spectra Systems HPLC equipped with a 
C18 5 µm, 4.6 mm × 150 mm, 100A analytical column (Waters, xBridge). Some compounds 
were purified using preparative HPLC on the same system with a preparative column (Prep 
C18, 5 µm, 19 mm × 250 mm, xBridge). Compounds were dissolved in DMSO and water and 
injected through a 50 µL loop. The solvent system used consisted of two mobile phases. 
Mobile phase A: NH4CO3/H2O, pH 10.4; mobile phase B: NH4CO3/MeOH, pH 10.4. Flow 
rates of 1.2 mL/min for analytical and 20 mL/min for preparative methods were used with 20 
min runs. The chromatographic purities of all the compounds were  98%. 
Briefly, the compounds investigated were prepared via a series of 4-chloroquinolines 
with differing substituents at position 7 on the quinoline ring. All of these are known 
compounds and are available commercially. Full synthetic details of those prepared in this 
study are provided as Supplementary content.  These were prepared in two different ways 
(see supplementary Schemes S1 and S2).
24,35-37
 In most cases, the starting materials were 3-
X-anilines (X = CH3, CN, NO2 or OCH3) and diethyl ethoxymethylenemalonate which were 
heated in equimolar ratio at 110 C for 45 – 60 min to yield a diethyl 2-((3-X-
phenylamino)methylene)malonate. This was then cyclized to a corresponding ethyl-4-
hydroxy-7-X-quinoline-3-carboxylate by refluxing in diphenyl ether (265 C) for 30 – 60 
min. The resulting ester was hydrolyzed by reflux in 2M aqueous NaOH for 30 – 60 min 
yielding the corresponding acid. This was decarboxylated by refluxing in diphenyl ether for 
45 – 60 min, except for 4-hydroxy-7-nitroquinoline-3-carboxylic acid which was first 
converted to a silver salt before decarboxylation.
38
 The alternative approach involved reacting 
triethyl orthoformate with a slight excess of 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum’s 
acid) to form an intermediate (ethoxymethylene Meldrum’s acid) to which 3-X-aniline (X = 
CONH2) was then added after one hour at 90 C (1 equivalent relative to Meldrum’s acid) in 
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situ. The resulting mixture was refluxed for 2 h to yield 3-((2,2-dimethyl-4-6-dioxo-1,3-
dioxan-5-ylidene)methylamino)benzamide which was isolated by precipitation from ice cold 
ethanol. The product was then directly cyclized to 4-hydroxyquinoline-7-carboxamide by 
refluxing in diphenyl ether for 5 min.
36,37
 This approach was also used as a second method for 
preparing the derivatives with X = NO2 or OCH3. In a final step, each of the 4-hydroxy-7-X-
quinolines was refluxed in excess phosphorus oxychloride (POCl3)  for 20 – 30 min to yield 
the corresponding 4-chloro-7-X-quinoline which was then isolated by precipitation after 
neutralization with ice cold 2 M NaOH. Three additional 4-chloro-7-X-quinolines (X = CF3, 
Cl or H) were sourced commercially (Sigma-Aldrich). 
The series of 4-amino-7-X-quinolines (X = CH3, Cl, CONH2, CN, H, NO2 or OCH3) 
were prepared by reacting the corresponding 4-chloro-7-X-quinoline with excess aqueous 
NH3 in a sealed tube at 70 C for 4 h (supplementary Scheme S3). Products were recovered 
by cooling and filtration and were then washed with 5% NH3 and isolated by preparative 
HPLC. For the compound with X = CF3, the 4-chloroquinoline was reacted with excess NaN3 
at 90 C in 8:3 DMF/H2O for 2 h. The resulting 4-azidoquinoline was extracted into CHCl3 
with NH4Cl and isolated by evaporation. This product was reduced to the 4-aminoquinoline 
with a small excess of PPh3 over 2 h in 1:1 THF/H2O at room temperature (supplementary 
Scheme S4). 
39,40
 The product was extracted with aqueous HCl and then into CHCl3 with 1 M 
NaOH and isolated by evaporation. Finally, 4,7-diaminoquinoline was prepared from 4-
amino-7-nitroquinoline by reduction with excess stannous chloride (SnCl2) over 2 h in HCl 
and glacial acetic acid at 60 C (supplementary Scheme S5).41 The product was obtained after 
base extraction into CHCl3 with NaOH after stirring, filtering and washing with acetone. 
The series of N-methyl-7-X-quinoline-4-amines (X = CH3, CF3, Cl, CONH2, CN, H, 
NO2 or OCH3) were prepared by reaction of the corresponding 4-chloro-7-X-quinoline with 
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excess methylamine in a sealed tube at 90 C for 6 h (supplementary Scheme S3). The 
products were purified by silica gel column chromatography. The compound with X = NH2 
was obtained by reduction of the nitro derivative with SnCl2 as described for 4,7-
diaminoquinoline above (supplementary Scheme S5). 
Lastly, the series of N
1
-(7-X-quinolin-4-yl)ethane-1,2-diamines (X = CH3, CF3, Cl, 
CN, H, NO2 or OCH3) was prepared by reaction of the 4-chloro-7-X-quinoline with 5 
equivalents of ethylene diamine in a sealed tube at 110 C for 4 – 6 h (supplementary Scheme 
S3). The crude products were obtained after base extraction into CHCl3 and were purified by 
preparative HPLC. 
Full synthetic details for previously reported compounds are provided as 
Supplementary content, while details for novel compounds are provided below. 
5.1.1 4-Aminoquinolin-7-carboxamide (9d) 
7d was heated in a sealed tube with excess aqueous ammonia at 70°C for 4 h. The mixtures 
were cooled to room temperature and the solid filtered. Solid was then washed with 5% NH3 
(aq.) and dried. Following silica gel chromatography and preparative HPLC where purity was 
above 98% the product was obtained as a white solid (50 mg, 40%). mp 132-134 °C. NMR - 
δH (400 MHz; DMSO) 5.12 (2H, br s, -NH2), 6.66 (1H, d, J 5.1 Hz, H-3), 7.80 (1H, d, J 8.8 
Hz, H-6), 8.34 (1H, d, J 8.8 Hz, H-5), 8.42 (1H, s, H-8), 8.56 (1H, d, J 5.1 Hz, H-2). δC (100 
MHz; DMSO) 116.8 (C-3), 121.8 (C-4a), 124.9 (C-5), 125.3 (C-6), 126.8 (C-8), 127.7 (C-7), 
143.1 (C-8a), 153.2 (C-2), 153.6 (C-4), 156.3 (-CONH2). HPLC tR = 9.51 min, purity  98%. 
HRMS (ESI) m/z 187.1980 (C10H9N3O, M
+ 
requires 187.1969). 
5.1.2 N,7-Dimethylquinolin-4-amine (10a) 
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7a and excess methylamine (33% in MeOH) were heated in a sealed tube at 90 °C for 6 h. 
The mixture was allowed to cool to room temperature and concentrated under reduced 
pressure. The product was then purified by silica gel chromatography using MeOH: EtOAc: 
Et3N (1:98:1) and obtained as a white solid (80 mg, 65%), mp 133-135 °C. NMR - δH (400 
MHz; DMSO) 2.51 (3H, s, Ar-CH3), 3.07 (3H, d, J 4.6 Hz, NHCH3), 6.66 (1H, d, J 7.0 Hz, 
H-3), 7.49 (1H, dd, J 1.5, 8.7 Hz, H-6), 7.75 (1H, br s, H-8), 8.43 (1H, d, J 6.9 Hz, H-2), 8.45 
(1H, d, J 8.7 Hz, H-5), 9.34 (1H, br s, NHCH3). δC (100 MHz; DMSO) 20.9 (Ar-CH3), 29.1 (-
NHCH3), 97.2 (C-3), 116.4 (C-4a), 121.4 (C-5), 125.7 (C-6), 127.1 (C-8), 138.4 (C-7), 147.3 
(C-8a), 149.8 (C-3), 151.1 (C-4). HPLC tR = 10.60 min, purity  98%. HRMS (ESI) m/z 
173.1062 (C11H12N2, [M+H]
+ 
requires 173.1079). 
5.1.3 N-Methyl-7-(triflouromethyl) quinolin-4-amine (10b) 
7b and excess methylamine (33% in MeOH) were heated in a sealed tube at 90 °C for 6 h. 
The mixture was allowed to cool to room temperature and concentrated under reduced 
pressure. The product was then purified by silica gel chromatography using MeOH: EtOAc: 
Et3N (1:98:1) and obtained as a white solid (70 mg, 60%), mp 227-229 °C. NMR - δH (400 
MHz; DMSO) 2.87 (3H, d, J 4.7 Hz, NHCH3), 6.47 (1H, d, J 5.4 Hz, H-3), 7.51 (1H, d, J 4.3 
Hz, NHCH3), 7.64 (1H, dd, J 1.9 Hz, J 8.8 Hz, H-6), 8.04 (1H, br s, H-8), 8.34 (1H, d, J 8.8 
Hz, 5), 8.48 (1H, d, J 5.3 Hz, H-2). δC (100 MHz; DMSO) 29.8 (NHCH3), 100.0 (C-3), 119.4 
(C-6), 121.3 (C-5), 124.1 (C-4a), 126.8 (Ar-CF3), 126.8 (C-8), 129.4 (C-7), 147.9 (C-8a), 
151.3 (C-2), 152.8 (C-4). HPLC tR = 9.49 min, purity  98%. HRMS (ESI) m/z 227.0782 
(C11H9F3N2, [M+H]
+ 
requires 227.0796). 
5.1.4 4-(Methylamino)quinolin-7-carboxamide (10d) 
7d and excess methylamine (33% in MeOH) were heated in a sealed tube at 90 °C for 6 h. 
The mixture was allowed to cool to room temperature and concentrated under reduced 
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pressure. The product was then purified by silica gel chromatography using MeOH: EtOAc: 
Et3N (1:98:1) and obtained as a white solid (60 mg, 50%), mp 165-166 °C. NMR - δH (400 
MHz; DMSO) 2.82 (1H, d, J 4.6 Hz, NHCH3), 5.88 (1H, d, J 3.9 Hz, NHCH3), 6.68 (1H, d, J 
5.5 Hz, H-3), 7.69 (1H, d, J 8.4 Hz, H-5), 7.91 (1H, d, J 0.8 Hz, H-8), 8.06 (1H, dd, J 1.3, 8.5 
Hz, H-6), 8.52 (1H, d, J 5.4 Hz, H-2). δC (100 MHz; DMSO) 31.1 (NHCH3), 102.7 (C-3), 
110.4 (C-4a), 123.0 (C-5), 128.0 (C-6), 135.0 (C-8), 147.3 (C-7), 149.6 (C-8a), 149.8 (C-2), 
151.9 (C-4). HPLC tR = 9.58 min, purity  98%. HRMS (ESI) m/z 201.0700 (C11H11N3O, M
+ 
requires 201.0902). 
5.1.5 4-(Methylamino)quinolin-7-carbonitrile (10e) 
7e and excess methylamine (33% in MeOH) were heated in a sealed tube at 90 °C for 6 h. 
The mixture was allowed to cool to room temperature and concentrated under reduced 
pressure. The product was then purified by silica gel chromatography using MeOH: EtOAc: 
Et3N (1:98:1) and obtained as a white solid (90 mg, 65%), mp 252-254 °C. NMR - δH (400 
MHz; DMSO) 2.87 (3H, d, J 4.7 Hz, NHCH3), 6.47 (1H, d, J 5.4 Hz, H-3), 7.51 (1H, d, J 4.4 
Hz, NHCH3), 7.68 (1H, dd, J 1.7, 8.7 Hz, H-6), 8.22 (1H, d, J 1.7 Hz, H-8), 8.28 (1H, d, J 8.7 
Hz, H-5), 8.48 (1H, d, J 5.4 Hz, H-2). δC (100 MHz; DMSO) 29.8 (NHCH3), 100.3 (C-7), 
111.9 (Ar-CN), 119.2 (C-3), 121.8 (C-5), 124.0 (C-4a), 125.0 (C-6), 135.0 (C-8), 147.7 (C-
8a), 151.2 (C-2), 153.0 (C-4). HPLC tR = 9.51 min, purity  98%. HRMS (ESI) m/z 184.0874 
(C11H9N3, [M+H]
+ 
requires 184.0796). 
5.1.6 N-Methyl-7-nitroquinolin-4-amine (10h) 
7h and excess methylamine (33% in MeOH) were heated in a sealed tube at 90 °C for 6 h. 
The mixture was allowed to cool to room temperature and concentrated under reduced 
pressure. The product was then purified by silica gel chromatography using MeOH: EtOAc: 
Et3N (1:98:1) and obtained as a yellow solid (40 mg, 55%), mp >330 °C. NMR - δH (400 
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MHz; DMSO) 2.94 (3H, s, NHCH3), 6.55 (1H, d, J 5.3 Hz, H-3), 8.10 (1H, dd, J 2.0, 9.2 Hz, 
H-6), 8.48 (1H, d, J 9.2 Hz, H-5), 8.54 (1H, d, J 1.8 Hz, H-8), 8.57 (1H, d, J 5.3 Hz, H-2). δC 
(100 MHz; DMSO) 31.1 (CH3), 102.7 (C-3), 110.5 (C-8), 123.0 (C-6), 128.0 (C-5), 135.0 (C-
4a), 147.3 (C-8a), 149.6 (C-3), 149.8 (C-7), 151.9 (C-4). HPLC tR = 5.30 min, purity  98%. 
HRMS (ESI) m/z 204.0792 (C10H9N3O2, [M+H]
+ 
requires 204.0773). 
5.1.7 7-Methoxy-N-methylquinolin-4-amine (10i) 
7i and excess methylamine (33% in MeOH) were heated in a sealed tube at 90 °C for 6 h. 
The mixture was allowed to cool to room temperature and concentrated under reduced 
pressure. The product was then purified by silica gel chromatography using MeOH: EtOAc: 
Et3N (1:98:1) and obtained as a white solid (100 mg, 60%), mp 75-78 °C. NMR - δH (400 
MHz; DMSO) 2.94 (3H, br s, -NHCH3), 3.85 (3H, s, Ar-OCH3), 6.44 (1H, d, J 6.4 Hz, H-3), 
7.13 (1H, dd, J 2.6, 9.2 Hz, H-6), 7.25 (1H, d, J 2.6 Hz, H-8), 8.22 (1H, d, J 9.3 Hz, H-5), 
8.26 (1H, s, Ar-NHCH3), 8.33 (1H, d, J 6.4Hz, H-2). δC (100 MHz; DMSO) 30.0 (-NHCH3), 
56.1 (Ar-OCH3), 103.7 (C-8), 112.3 (C-3), 117.1 (C-4a), 124.5 (C-6), 144.3 (C-5), 146.0 (C-
8a), 154.3 (C-2), 161.8 (C-4), 164.8 (C-7). HPLC tR = 8.91 min, purity  98%. HRMS (ESI) 
m/z 189.1026 (C11H12N2O, [M+H]
+ 
requires 189.1028). 
5.1.8 N
4
-Methylquinolin-4,7-diamine (10g) 
Stannous chloride (SnCl2) (0.87 g, 4.57 mmol) dissolved in concentrated HCl (3 mL) was 
added slowly to a stirred solution of 10h (0.12 g, 0.57 mmol) in glacial acetic acid (20 mL). 
The mixture was stirred at 60 °C for 2 hr. After the mixture was cooled, acetone (50 mL) was 
added and it was stirred vigorously. Precipitate was collected by filtration, washed with 
acetone, and suspended in water (250 mL). The suspension was made basic (pH 12) with 
sodium hydroxide and the product was extracted with chloroform (5 × 50 mL). The crude 
product was purified by silica gel chromatography with chloroform-methanol (10:1) 
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containing 0.5% triethylamine. Solvent was evaporated to obtain 10g (84 mg, 70%) as a 
yellow solid mp 283-285 °C. NMR - δH (400 MHz; DMSO) 2.91 (3H, d, J 4.7Hz, -NHCH3), 
6.53 (1H, d, J 5.4Hz, H-3), 7.45 (1H, bs, -NHCH3), 8.08 (1H, dd, J 2.3, 9.2Hz, H-6), 8.36 
(1H, d, J 9.2Hz, H-5), 8.52 (1H, d, J 2.3Hz, H-8), 8.54 (1H, d, J 5.3Hz, H-2). δC (100 MHz; 
DMSO) 29.8 (-NHCH3), 100.7 (C-3), 117.1 (C-8), 123.1 (C-4a), 124.5 (C-5), 124.9 (C-6), 
148.0 (C-7), 150.3 (C-8a), 151.5 (C-2), 153.6 (C-4). HPLC tR = 7.86 min, purity  98%. 
HRMS (ESI) m/z 174.1031 (C10H11N3, [M+H]
+ 
requires 174.1029). 
5.1.9 N
1
-(7-methylquinolin-4-yl)ethane-1,2-diamine (11a) 
7a (1 eq.) and excess (5 eq.) ethylene diamine were heated in a sealed tube at 120 °C for 4-6 
h. The reaction mixture was cooled to room temperature and a mixture of 1 M NaOH and 
CHCl3 (1:4) was added to the mixture. The organic layer was washed with brine and dried 
with Na2SO4. Solvent was removed and resulting solid purified by column chromatography 
and further purified by HPLC where purity was found to be below 98%. The product was 
obtained as a white solid (80 mg, 50%). NMR - δH (400 MHz; DMSO) 2.44 (3H, s, Ar-CH3), 
2.83 (3H, t, J 6.3 Hz, CH2), 3.24 (2H, t, J 6.2 Hz, CH2), 6.38 (1H, d, J 5.3 Hz, H-3), 6.87 (1H, 
br s, Ar-NH-), 7.22 (1H, dd, J 1.3, 8.5 Hz, H-6), 7.55 (1H, br s, H-8), 8.08 (1H, d, J 8.5 Hz, 
H-5), 8.32 (1H, d, J 5.3 Hz, H-2). δC (100 MHz; DMSO) 21.6 (Ar-CH3), 38.7 (C-11), 41.8 
(C-10), 98.5 (C-3), 122.5 (C-4a), 124.5 (C-5), 129.0 (C-6), 129.5 (C-8), 139.4 (C-7), 145.8 
(C-8a), 148.7 (C-2), 150.2 (C-4). HPLC tR = 11.79 min, purity  98%. HRMS (ESI) m/z 
202.1350 (C12H15N3, [M+H]
+ 
requires 202.1344). 
5.1.10 4-(2-Aminoethylamino)quinoline-7-carbonitrile (11e) 
7e (1 eq.) and excess (5 eq.) ethylene diamine were heated in a sealed tube at 120 °C for 4-6 
h. The reaction mixture was cooled to room temperature and a mixture of 1 M NaOH and 
CHCl3 (1:4) was added to the mixture. The organic layer was washed with brine and dried 
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with Na2SO4. Solvent was removed and resulting solid purified by column chromatography 
and further purified by HPLC where purity was found to be below 98%. The product was 
obtained as a white solid (60 mg, 50%), mp 161-163 °C. NMR - δH (400 MHz; DMSO) 2.81 
(3H, t, J 6.4 Hz, CH2), 3.26 (3H, t, J 5.3 Hz, CH2), 6.57 (1H, d, J 5.5 Hz, H-3), 7.35 (1H, br s, 
Ar-NH), 7.68 (1H, dd, J 1.7, 8.7 Hz, H-6), 8.22 (1H, d, J 1.7 Hz, H-8), 8.39 (1H, d, J 8.7 Hz, 
H-5), 8.46 (1H, d, J 5.4 Hz, H-2). δC (100 MHz; DMSO) 46.3 (C-10), 100.6 (C-7), 111.8 (Ar-
CN), 119.2 (C-3), 121.9 (C-5), 124.4 (C-4a), 124.9 (C-6), 135.1 (C-8), 147.9 (C-8a), 150.6 
(C-2), 152.9 (C-4). HPLC tR = 12.92 min, purity  98%. HRMS (ESI) m/z 213.1156 
(C12H12N4, [M+H]
+ 
requires 213.1140). 
5.1.11 N
1
-(7-nitroquinolin-4-yl)ethane-1,2-diamine (11h) 
7h (1 eq.) and excess (5 eq.) ethylene diamine were heated in a sealed tube at 120 °C for 4-6 
h. The reaction mixture was cooled to room temperature and a mixture of 1 M NaOH and 
CHCl3 (1:4) was added to the mixture. The organic layer was washed with brine and dried 
with Na2SO4. Solvent was removed and resulting solid purified by column chromatography 
and further purified by HPLC where purity was found to be below 98%. The product was 
obtained as a yellow solid (90 mg, 55%), mp 170-172 °C. NMR - δH (400 MHz; DMSO) 2.82 
(2H, t, J 6.1 Hz, CH2), 3.22 (2H, t, J 6.1 Hz, CH2), 6.79 (1H, d, J 5.5 Hz, H-3), 7.74 (1H, d, J 
8.4 Hz, H-5), 7.91 (1H, d, J 1.2 Hz, H-8), 8.09 (1H, dd, J 1.3, 8.5 Hz, H-6), 8.54 (1H, d, J 5.5 
Hz, H-2). δC (100 MHz; DMSO) 45.9 (C-10), 103.2 (C-3), 110.6 (C-8), 122.5 (C-6), 128.1 
(C-5), 134.6 (C-4a), 147.4 (C-8a), 148.8 (C-2), 149.8 (C-7), 151.8 (C-4). HPLC tR = 10.38 
min, purity  98%. HRMS (ESI) m/z 256.097 (C11H12N4O2, [M+H+Na]
+  
requires 256.0998). 
5.2 Biophysical Measurements and in vitro P. falciparum assay 
Association constants of the various 4-aminoquinolines with Fe(III)PPIX were 
determined in 40% aqueous (v/v) DMSO, pH 7.5 by spectrophotometric titration using 
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methods previously described and without modification.
13
 The -hematin inhibitory activity 
was also determined by methods previously reported, again without modification.
42
 The assay 
uses 4.5 M acetate to mediate -hematin formation and 5% aqueous pyridine reacts with 
unconverted Fe(III)PPIX to form a low-spin bis-pyridyl complex which can be measured 
colorimetrically. 
Compounds 11a – h were tested in vitro against the chloroquine-sensitive NF54 strain 
of P. falciparum using the [
3
H]-hypoxanthine incorporation assay, basically as described 
elsewhere.
43
 
5.3 Computational methods 
DFT calculations on neutral and cationic (quinolinium) structures of 7-substituted 4-
aminoquinolines (R = H) were performed using the Gaussian09 software package.
44
 
Geometry optimizations of all structures were completed in vacuum using the B3LYP 
functional and 6-31G(d,p) basis set, B3LYP/6-31G(d,p), except in the case of the iodine 
analog where the iodine atom was described by the 6-311G(d) basis set (retrieved from the 
EMSL Basis Set Exchange portal)
45
 which makes use of a d-type polarization function.
46
 
Frequencies of final geometry-optimized structures were generated to ensure a stationary 
point was obtained. In order to test the reliability of the chosen functional and basis set, the 
structure of CQ was computed and compared to experimental crystal structure data.
47
 The 
average bond length and angle deviations of the quinoline ring were 0.01 Å and 0.5° 
respectively, indicating this method can produce computed structures in good agreement with 
experimental data. CHelpG charges were calculated using the B3LYP functional in vacuum 
or under the implicit water conditions of the SMD solvent model,
33
 and were constrained to 
reproduce the dipole moment. Atoms were described using the larger 6-311+G(2df,p) basis 
set, B3LYP/6-311+G(2df,p), or in the case of the iodine atom in the X = I molecule, the 6-
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311G(d) basis set (described above for geometry optimization). For bromine and iodine 
atoms, atomic radii used to determine CHelpG charges were set to the van der Waals radii of 
1.85 and 1.98 Ǻ, respectively.48 CHelpG as well as Mulliken atomic charges (calculated in 
the same manner as for CHelpG charges) for all 7-substituted 4-aminoquinolines (R = H) in 
both neutral and quinolinium forms, are listed in supplementary content Tables S2-S5. 
Electrostatic surface potentials were generated using the USCF Chimera software package
49
 
by mapping the electrostatic potential (obtained using the same functional and basis sets as 
described for CHelpG atomic charges) onto a density isosurface of 0.002 e.au
-3
. 
5.4 Correlation analyses 
Single linear correlation analysis (SLCA) and multiple linear correlation analysis 
(MLCA) were performed using the computed CHelpG and Mulliken atomic charges for the 
neutral and quinolinium species in both vacuum and in the implicit SMD water model. In 
order to facilitate correlations, the atomic charges of any X substituent consisting of two or 
more atoms were summed to give an overall atomic charge of the X group. For SLCA, a 
correlation between atomic charge and log K was deemed significant if the P-statistic was 
less than 0.05. While the same criterion were required for statistical significance between 
atomic charge and log BHIA50, an additional condition was also imposed, namely that the 
relationship should predict that the log BHIA50 value for the X = NH2 molecule be greater 
than the experimental assay limit (1.30). For MLCA, correlations between atomic charge and 
log K were deemed significant if they produced a F value greater than F
crit
 at the 95 % 
confidence level and both correlation coefficients produced a t value greater than t
crit
 at the 95 
% confidence level. The same requirements were enforced for correlations between atomic 
charges and log BHIA50, but as in the case of SLCA, the additional criterion of predicting that 
the log BHIA50 of the X = NH2 molecule be greater than 1.30 was also imposed. 
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